Table 2.
Patient Cohort Demographics and Univariate Cox Regression Analysis of Clinical
| Variable | No. of patient (%) | Overall survival | ||
|---|---|---|---|---|
| HR | 95% CI | p-value | ||
| Age, yr | 0.265 | |||
| ≤65 | 21 (55.3) | Reference | ||
| >65 | 17 (44.7) | 1.66 | 0.68–4.06 | |
| Sex | 0.603 | |||
| Male | 19 (50.0) | Reference | ||
| Female | 19 (50.0) | 0.80 | 0.34–1.88 | |
| Tumor location | 0.262 | |||
| Head/uncinate process | 18 (47.4) | Reference | ||
| Body/tail | 20 (52.6) | 1.68 | 0.68–4.18 | |
| Operation type | 0.260 | |||
| Total pancreatectomy | 2 (5.3) | Reference | ||
| Pancreaticoduodenectomy/PPPD | 17 (44.7) | 0.29 | 0.06–1.47 | |
| Distal pancreatectomy | 19 (50.0) | 0.52 | 0.11–2.42 | |
| Major vessel excision | 0.921 | |||
| Not performed | 22 (57.9) | Reference | ||
| SMV/PV resection | 14 (36.8) | 0.88 | 0.35–2.22 | |
| Celiac axis resection | 2 (5.3) | 0.70 | 0.09–5.38 | |
| Chemotherapy | 0.810 | |||
| Gemcitabine-based | 23 (60.5) | Reference | ||
| FOLFIRINOX | 15 (39.5) | 0.89 | 0.36–2.23 | |
| Radiotherapy | 0.085 | |||
| Not performed | 27 (71.1) | Reference | ||
| Performed | 11 (28.9) | 0.40 | 0.14–1.14 | |
| RECIST 1.1 | 0.021 | |||
| Complete response | 0 | |||
| Partial response | 29 (76.3) | Reference | ||
| Stable disease | 9 (23.7) | 2.86 | 1.17–6.99 | |
| Progressive disease | 0 | |||
HR, hazard ratio; CI, confidence interval; PPPD, pylorus-preserving pancreaticoduodenectomy; SMV, superior mesenteric vein; PV, portal vein; FOLFIRINOX, 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; RECIST, response evaluation criteria in solid tumors.